WntResearch Overview

  • Founded
  • 2007
Founded
  • Status
  • Public
  • Employees
  • 3
Employees
  • Stock Symbol
  • WNT
Stock Symbol
  • Share Price
  • $0.04
  • (As of Friday Closing)

WntResearch General Information

Description

WntResearch AB is a cancer research company. The company develops anti-metastatic therapies based on the mechanisms underlying the metastatic process.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
SAT
Primary Office
  • Medeon Science Park
  • Per Albin Hanssons Väg 41
  • 205 12 Malmo
  • Sweden
+46 040-650 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

WntResearch Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.04 $0.04 $0.04 - $0.10 $5.7M 133M 153K -$0.04

WntResearch Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 92 980 4,539 16,068
Revenue 0 0 0 0
EBITDA (4,360) (4,105) (2,303) (2,622)
Net Income (4,419) (4,165) (2,338) (2,652)
Total Assets 4,152 5,579 3,531 2,177
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

WntResearch Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore WntResearch‘s full profile, request access.

Request a free trial

WntResearch Patents

WntResearch Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3137093-A1 Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer Pending 16-Apr-2019 00000000000
AU-2020259121-A1 Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer Pending 16-Apr-2019 00000000000
AU-2019395708-A1 Linear solution phase routes for wnt hexapeptides Pending 14-Dec-2018 00000000
CA-3123331-A1 Linear solution phase routes for wnt hexapeptides Pending 14-Dec-2018 00000000
EP-3894426-A1 Linear solution phase routes for wnt hexapeptides Pending 14-Dec-2018 C07K7/06
To view WntResearch’s complete patent history, request access »

WntResearch Executive Team (7)

Name Title Board Seat Contact Info
Tommy Andersson Chief Scientific Officer, Board Member & Owner
Peter Morsing Ph.D Advisor
Anders Rabbe Chief Executive Officer
Per-Ola Forsberg Chief Financial Officer
Dennis Henriksen Ph.D Chief Technology Officer
You’re viewing 5 of 7 executive team members. Get the full list »

WntResearch Board Members (11)

Name Representing Role Since
Carl Borrebaeck Ph.D Self Board Member 000 0000
Gudrun Anstrén WntResearch Board Member 000 0000
Kjell Stenberg WntResearch Board Member 000 0000
Lars Larsson Ph.D WntResearch Board Member 000 0000
Martin Olovsson Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

WntResearch Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

WntResearch Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore WntResearch‘s full profile, request access.

Request a free trial